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Abstract  
 
TP53 as a Biomarker in Head and Neck Squamous Cell Carcinoma 
Thomas J. Ow, MD 
Supervisory Professor: Jeffrey N. Myers, MD, PhD 
 
 Currently, there are no molecular biomarkers that guide treatment decisions 
for patients with head and neck squamous cell carcinoma (HNSCC).  Several 
retrospective studies have evaluated TP53 in HNSCC, and results have suggested 
that specific mutations are associated with poor outcome.  However, there exists 
heterogeneity among these studies in the site and stage of disease of the patients 
reviewed, the treatments rendered, and methods of evaluating TP53 mutation.  
Thus, it remains unclear as to which patients and in which clinical settings TP53 
mutation is most useful in predicting treatment failure. 
 In the current study, we reviewed the records of a cohort of patients with 
advanced, resectable HNSCC who received surgery and post-operative radiation 
(PORT) and had DNA isolated from fresh tumor tissue obtained at the time of 
surgery.  TP53 mutations were identified using Sanger sequencing of exons 2-11 
and the associated splice regions of the TP53 gene.   We have found that the group 
of patients with either non-disruptive or disruptive TP53 mutations had decreased 
overall survival, disease-free survival, and an increased rate of distant metastasis.  
When examined as an independent factor, disruptive mutation was strongly 
associated with the development of distant metastasis.   
vi 
 
As a second aim of this project, we performed a pilot study examining the 
utility of the AmpliChip® p53 test as a practical method for TP53 sequencing in the 
clinical setting.  AmpliChip®  testing and Sanger sequencing was performed on a 
separate cohort of patients with HNSCC.  Our study demonstrated the ablity of the 
AmpliChip® to call TP53 mutation from a single formalin-fixed paraffin-embedded 
slide.  The results from AmpliChip®  testing were identical with the Sanger method 
in 11 of 19 cases, with a higher rate of mutation calls using the AmpliChip® test.  
 TP53 mutation is a potential prognostic biomarker among patients with 
advanced, resectable HNSCC treated with surgery and PORT.  Whether this 
subgroup of patients could benefit from the addition of concurrent or induction 
chemotherapy remains to be evaluated in prospective clinical trials. Our pilot study 
of the p53 AmpliChip®  suggests this could be a practical and reliable method of 
TP53 analysis in the clinical setting.  
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Introduction 
 
 The Clinical Challenges of Head and Neck Squamous Cell Carcinoma 
Squamous cell carcinoma of the head and neck (HNSCC) ranks among the 
top ten cancers worldwide for both incidence and mortality, with over 600,000 new 
cases diagnosed and over 300,000 estimated deaths each year(1).  Approximately 
45,000 new cases of HNSCC were diagnosed, with approximately 8,000 deaths 
occurring in the United States during 2010(2).  Head and neck squamous cell 
carcinoma (HNSCC) can arise anywhere in the upper aerodigestive tract, 
particularly in the oral cavity, larynx, and pharynx. 
The treatment options for HNSCC primarily include surgical resection, 
external beam radiation, and the use of chemotherapy(3, 4), most commonly 
platinum-based cytotoxic regimens(5, 6) or the EGFR inhibitor, cetuximab(7, 8).  
The strategies are largely chosen based on site of disease and staging according to 
the AJCC TNM criteria(9).  In general, surgical resection is used as the primary 
modality to treat squamous carcinomas of the oral cavity due to the increased 
morbidity of definitive radiation to this region, particularly the risk of 
osteoradionecrosis of the mandible (10).  Organ-sparing protocols, with radiation as 
the primary modality, are typically recommended for pharyngeal and laryngeal 
squamous cancers(6).  Definitive treatment of advanced-stage disease (AJCC 
Stage III and IV) requires multimodality approaches, generally surgical resection 
with post-operative radiation (PORT), or concurrent chemoradiation (CCR) for 
organ-sparing approaches (3, 4, 6).  Several studies have evaluated 
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induction/neoadjuvant chemotherapeutic strategies for the treatment of stage III and 
IV HNSCC(5, 6, 11, 12), further adding to the complexity of treatment options under 
consideration for the patient with advanced HNSCC, though the indications and 
measurable benefit from these strategies remain to be further delineated.  
In 2004, two multi-institutional, phase-III randomized controlled trials 
evaluated the efficacy of adding concomitant cisplatin to PORT for advanced, 
resectable HNSCC, and each independently supported the use of post-operative 
chemoradiation (POCRT) in this setting(13, 14).  When considering these two 
studies together, it became clear that patients with extracapsular spread of lymph 
node disease (ECE) and those with positive surgical margins after surgical 
resection represented a high-risk group for recurrence and mortality, and these 
factors are now strong indications for POCRT(15). 
Figure-1 summarizes the current approach to treating patients with HNSCC 
based on the guidelines detailed above.   
 
 
Figure-1 – Algorithm summarizing the current approach to the treatment of HNSCC. 
*in specific cases  (eg. laryngeal microsurgery for T1 glottic cancer) 
**in specific cases (eg. advanced T4 laryngeal cancer) 
 Please note that the management of an individual patient with HNSCC is much more complex, with 
multiple considerations dependent on disease site, stage, and patient factors.  The algorithm is presented 
here to highlight key factors that play a role in determining the treatment regimen of a typical patient, and is 
not meant to provide treatment guidelines to be used in the management of patients in the clinical setting.  
  
 
3 
 
This is a simplified view of the decision tree for the clinical team for the typical 
patient with HNSCC, but the algorithm highlights the important factors leading to the 
multidisciplinary treatment strategy of this disease.  Two principles are evident 
regarding the management of HNSCC.  First, multimodality strategies are crucial to 
increase the likelihood of control of advanced disease, and these options become 
more complicated as disease stage increases.  Second, contemporary 
management decisions remain largely founded upon disease site, stage, and 
additional clinical and pathologic factors.   
Despite the multitude of treatment options available to treat HNSCC, many 
patients continue to suffer from the morbidity of treatment, treatment failure, disease 
recurrence, and the development of metastasis.  The recurrence and survival rates 
vary greatly depending on disease site in the head and neck.  For example, 
outcomes with early stage tumors of the glottic larynx can be quite favorable with 5-
year disease-free rates as high as 80 – 90%(16), whereas treatment of early-stage 
oral tongue cancer can have local failure rates as high as 30-50%(17).  Patients 
with advanced, resectable head and neck squamous cell carcinoma, even after 
POCRT (the most rigorous strategy available), are faced with progression-free 
survival rates in the range of 50-60%(13, 14).  As described above, the treatment 
decisions for patients with HNSCC are made based upon disease site and stage, 
and it is evident that these clinicopathologic considerations are limited in their ability 
to accurately predict the outcome of patients with specific treatments.  Futhermore, 
the unacceptable but consistent failure rate, even for early-stage lesions in some 
cases, suggest that additional factors are necessary to aid our ability to predict 
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which HNSCC tumors will be best managed with either simple or more 
comprehensive treatments selecting from surgery, radiation, or our growing number 
of chemotherapeutic options.  To this end, there is currently a paucity of molecular 
biomarkers that are employed today to guide the management of HNSCC.  A single, 
yet notable exception that has been elucidated in recent years is the presence of 
HPV infection and/or p16 expression in oropharyngeal cancer.     
Recent data has identified an increasing incidence of patients diagnosed with 
oropharyngeal squamous cell carcinoma (18-20), and this disease appears to be 
increasing most among middle-aged, white male patients who are non-smokers(19, 
21, 22).  Epidemiology studies have established that the human papilloma virus 
(HPV), particularly the high-risk serotypes 16 and 18 (22), are present at a high rate 
in tumor specimens of these patients.  There is substantial prospective and 
retrospective evidence that the subgroup of patients with HPV-positive 
oropharyngeal cancer has a more favorable prognosis as compared to patients with 
oropharynx cancer that is negative for HPV(21, 23).  Active HPV infection results in 
several alterations in key cell signaling pathways that promote tumorigenesis.  In 
particular, expression of the E6 and E7 viral proteins lead to the inactivation of two 
key tumor suppressors, p53 and Rb, along with several other key factors in DNA 
damage signaling and cell cycle regulation(24).  The ensuing dysregulation of 
normal cell cycle regulation and inhibition of feedback loop mechanisms lead to 
overexpression of p16, and recent studies have shown that p16 overexpression is 
also associated with improved outcome in HNSCC (21, 22).  P16 overexpression is 
certainly a surrogate for active HPV infection in tumor cells, and there are reports 
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supporting p16 overexpression as a prognostic marker independent of HPV, but this 
remains to be further clarified(21, 22).  Evaluation of HPV infection and/or p16 
overexpression have become prognostic biomarkers in the workup of oropharyngeal 
squamous carcinoma(21, 23).  HPV appears to play a much less significant role in 
other sites of HNSCC, and the overall utility of HPV as a biomarker in these 
subsites is still being explored (25-27). Thus, molecular biomarkers that can be 
used for prognosis and for guiding management decisions are lacking for HPV-
negative oropharyngeal carcinomas as well as for other sites of HNSCC.    
HPV and p16 have become prognostic biomarkers for patients with 
oropharyngeal squamous cell carcinoma, and the current outstanding question is if 
patients with HPV-positive oropharynx cancer can receive a de-escalated treatment 
regimen (eg. lower total dose of radiation, or withholding concurrent chemotherapy) 
without decreasing disease control and survival, thus potentially making this the first 
biologic marker used to alter management decisions that would otherwise proceed 
based on site and stage alone.  
 Despite the advances in our understanding of HPV in oropharyngeal cancer, 
there are still no biomarkers currently used to assist with clinical decision-making in 
the treatment of patients with HNSCC, leaving the clinician to rely strictly upon 
clinicopathologic factors to determine treatment for HPV-negative oropharynx 
cancer, and HNSCC from other anatomic sites.  There is a need for biomarkers that 
identify those patients with HNSCC that could benefit from additional treatment, and 
the current study aims to explore the potential utility of TP53 mutation in this role.    
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Description of the TP53 gene and p53 tumor suppressor       
TP53 is the most frequently mutated gene in human cancer(28-30), and has 
been well-studied since its first description over 30 years ago (31).  P53 was 
determined to be a tumor suppressor roughly 10 years after its discovery(32, 33), 
and since that time alteration of p53 has been shown to play a key role in the 
pathogenesis and progression of numerous, if not all human cancers.  P53 is 
involved in coordinating the response to cell stressors such as DNA damage, 
hypoxia, and oncogenic stress(34).  P53 functions largely as a sequence-specific 
transcription factor with hundreds of targets in the human genome(35).  Described 
targets include genes that induce cell cycle arrest (eg. p21, GADD45), activate DNA 
repair mechanisms (eg. p48, XPC), and drive apoptosis (eg. Bax, Apaf1, Noxa)(35, 
36).  P53 also has cytoplasmic and mitochondrial targets that regulate apoptosis, 
autophagy, and metabolism(36).  Because radiation therapy and cytotoxic 
chemotherapeutic agents act through many of these same pathways, p53 also 
plays an important role in the response to these cancer therapies(37, 38).  In 
summary, p53 responds to many stressors that promote carcinogenesis, and it 
protects against the development of malignancy by guiding the cell either toward a 
state of repair or self-destruction.  A summary of p53 function and results of 
mutation are summarized in Figure-2.         
The myriad functions of p53 can be attributed to its complicated structure and 
regulation.  P53 is a protein made up of 393 amino acids encoded by 11 exons 
found in the TP53 gene on chromosome 17(39, 40).  The protein product is 
composed of several domains, including a DNA-binding domain, an oligomerization 
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Figure 2.  Summary of p53 function and consequences of TP53 mutation.   
(*Model of mutant p53 shows codon sites where mutations were found in the current study) 
region, and a tetramerization site(39) (see Figure-3, results section).  At the latter 
region, p53 forms a dimer with another p53 molecule, which in turn combines with a 
second p53 dimer to form the final functional complex(39).  Under basal conditions, 
p53 is maintained at a very low level secondary to regulation by MDM2, which 
directly binds and ubiquitinates p53, resulting in proteosomal degradation of  the 
p53 protein(34).  Cell stressors generally cause p53 stabilization via inhibition of 
MDM2 degradation.  For example, ATM, a protein activated by DNA damage, 
phosphorylates p53, stabilizing the molecule and inhibiting MDM2-mediated 
degradation(34).  This archetypal model of p53 regulation is just one example of 
p53 regulation.  There are several amino acids of the p53 protein that are targets of 
enzymatic modification, which include phosphorylation, ubiquitination, neddylation, 
sumoylation, acetylation, and methylation.  These sites are found in every domain of 
the p53 protein, including the transactivation domain, the DNA-binding region, and 
the tetramerization site(41).  In addition to enzymatic modification, there are 
 * 
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additional levels of regulation of the p53 molecule and its function (eg. alternative 
splicing, regulation by microRNA, etc.), however a full discussion of these 
processes is beyond the scope of this report.  Each alteration in the molecular 
structure of p53 may change its stability, its capacity to translocate to the nucleus, 
or its influence on transcriptional and cytoplasmic targets.   
In summary, the complexity of the TP53 gene and the p53 protein leads to its 
diverse role in tumor biology, and the effects of mutation of TP53 are equally 
complex.  
 
Overview of TP53 mutation in Human Cancer  
The patterns of mutations found in TP53 in human cancer have several 
interesting and unique features.  Whereas most tumor suppressor genes are altered 
by truncating mutations or deletions, the mutation pattern of p53 is unique in that 
there appears to be a strong selection bias for missense mutations, particularly 
involving amino acids in the DNA-binding domain(29, 30, 42, 43).  For this reason, 
several studies of TP53 in HNSCC have relied on sequencing exons from this 
region alone to assess for mutations in the TP53 gene(44, 45).  Missense mutation 
often leads to p53 stabilization and accumulation of p53 in tumor cells that can be 
noted on immunohistochemical examination(46-48).   
Mutation in p53 can be categorized as either ‘loss of function’ or ‘gain of 
function’.  If a mutation renders p53 expression absent, then all p53 function is lost.  
However, mutant forms of p53 (especially those carrying missense mutations) often 
retain their expression, and therefore may remain partially functional.  Loss of p53 
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function may also occur secondary to a dominant negative effect (DNE) by mutant 
p53.  DNE occurs when mutant p53 directly inhibits the remaining wild-type p53 
produced by the normal allele.  Mutant p53 can also exhibit new, oncogenic 
properties that are not attributable to the loss of p53 alone.  These ‘gain-of-function’ 
mutations were first identified in 1991(49) and later definitively confirmed in 
1993(50) through in vivo mouse studies in which B-cell tumors that were p53-null 
became significantly more aggressive after mutant forms of p53 were introduced.  
Since that time, many examples of p53 gain-of-function mutations have been 
identified(51).  The varying sequelae of mutation in TP53 are summarized above in 
Figure-2. 
It should be noted that mutation is not the only mechanism for p53 
inactivation.  P53 can be inactivated by tumor-associated viral proteins, as in the 
abrogation of p53 by the HPV E6 protein, as described above.   MDM2 amplification 
is another well described mechanism of disruption of the p53 axis described in 
human cancer (52), however MDM2 expression is more often diminished or lost in 
HNSCC, and TP53 mutation predominates (53).  
The 30-year history of p53 research has contributed significantly to our 
understanding of this important protein, but the complexity of TP53 mutation has 
limited the utility of this information in the clinical setting.   
 
The role of TP53 mutation in HNSCC 
TP53 mutation is very common in HNSCC, and cancer of the head and neck 
ranks among breast, lung, and colorectal cancer as those in which TP53 mutations 
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are most commonly found (IARC database version R15, (42)).  There are, of 
course, several genetic alterations that consistently contribute to the development of 
HNSCC.  Cyclin D1 or p16 overexpression, signaling through EGFR or MET, 
SMAD4 mutation, PTEN loss, and PIK3CA activating mutations have all been noted 
to contribute to the development of head and neck squamous cell carcinoma at a 
relatively high frequency (54) .  Two recent studies using whole exome sequencing 
of HNSCC specimens have provided the most detailed examination of mutation in 
this disease to date (55, 56).  Several mutations and gene alterations were 
discovered and described, and interestingly both studies found frequent alterations 
of NOTCH-1.  Additionally, as expected, TP53 mutations predominated in both 
studies.   Mutation in TP53 is present in 40 - 60% of reported cases of HNSCC (42, 
44, 57, 58).  Wild-type p53 is disrupted in an additional subset of HNSCC infected 
by HPV, commonly found in tumors of the oropharynx, as described above.  Similar 
to other models of cancer progression(59), loss of heterozygosity of TP53 was 
identified as an early event in the development of many head and neck cancers(58, 
60), and mutations in TP53 have been associated with poor outcome in several 
studies(44, 45, 57, 61).   
In 1998, Koch, et al.(44) examined exons 5-9 of TP53 in tumors harvested 
from 110 patients with HNSCC who received either primary radiation or adjuvant 
radiation for treatment of their disease, and 48 (44%) were found to have a 
mutation.  Though not associated with decreased overall survival, TP53 mutation 
was found to be associated with decreased progression-free survival, which 
remained an independent factor after multivariate regression analysis.  Erber et. al, 
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in 1998(45), evaluated exons 5-8 of TP53 in tumors from 86 previously untreated 
patients with HNSCC, and did not find a significant difference in overall survival 
between the group with TP53 mutation versus the group with no mutation identified.  
The authors did, however, classify TP53 mutation into structural and contact 
mutations based on the location of the mutation in the L3, H2, S10, or Zinc binding 
amino acids (contact mutations) proposed by Cho, et al(62) to make up the core 
DNA-binding domain.  They found that patients with TP53 contact mutations had 
decreased overall and recurrence-free survival.   More recently, a large study 
conducted by Poeta, et al. in 2007(57) evaluated TP53 in 420 patients with HNSCC 
and classified mutations into disruptive (ie. nonsense mutations or missense 
mutations in the L2-L3 region leading to an amino acid change with a different 
polarity or charge) or nondisruptive (ie. all other non-conservative mutations).  In 
this study, representing the largest to date, TP53 mutation was associated with 
decreased overall survival, and disruptive mutation was associated with the group 
of patients with the poorest survival.  After multivariate analysis, disruptive TP53 
mutation remained strongly associated with decreased overall survival.  Most 
recently, Lindenbergh, et al. in June, 2011(61) published a study evaluating 141 
patients with HNSCC who either received surgery or surgery and radiation, and 
found that truncating TP53 mutations were more strongly associated with poor 
outcome than disruptive mutations.   
There exists ample data to suggest that TP53 can be used to predict 
outcome in HNSCC, however TP53 mutation in HNSCC tumors has not become 
part of the routine evaluation in the clinical setting.   
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Current limitations to TP53 as a biomarker in HNSCC 
Despite several studies that have supported the potential of TP53 mutation 
as a predictor of poor outcome in HNSCC, TP53 mutational analysis has not 
become a routine diagnostic in the clinical setting.  There are currently several 
limitations to the implementation of TP53 mutation analysis.  One major limitation is 
that previous studies have largely reviewed HNSCC patients with varying tumor 
sites, disease stage, and treatments received(44, 45, 57, 61), and thus it is not clear 
which group of patients would benefit most from the evaluation of TP53 mutation 
analysis.  Second, methods used to detect TP53 mutation have varied between 
studies, as well, adding to the difficulty of arriving at generalizable conclusions from 
a collective review of the literature(63).  Finally, technical and economic limitations 
have further hindered the implementation of TP53 mutation analysis in the clinical 
setting.  A more detailed review of these limitations is discussed in the following 
sections.      
 
Patients evaluated in studies examining TP53 in HNSCC have been 
heterogeneous with regard to site, stage, and treatment.  Several factors play a 
role in the eventual outcome of patients with HNSCC, including disease site, stage, 
HPV status, and the treatments that are provided.  The difficulty of arriving at 
generalizable conclusions from the published literature studying p53 in HNSCC due 
to these factors are well-summarized in the systematic review by Tandon(63).   
Among the studies that have evaluated TP53 mutation and prognosis among 
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patients with HNSCC, only a few have evaluated HPV status(61, 64), which is now 
known to dramatically alter patient prognosis with current treatment stategies.  
Furthermore, in the largest study to evaluate TP53, the patients examined received 
a diverse array of treatments(57), and several other studies include at least two, if 
not several treatment strategies among the patient cohorts(44, 45, 61).  Therefore, 
though TP53 mutation may be relevant to patients with HNSCC as a whole, it is 
currently unclear for which patients TP53 mutation may be most useful in predicting 
outcome or for guiding treatment decisions.   
 
The method of detecting TP53 mutation has varied from study to study.  There 
are a multitude of methods for evaluating p53 in tumor specimens, most common of 
which are immunohistochemical (IHC) evaluation for p53 protein expression (with a 
vast array of potential antibodies) and direct sequencing of genomic DNA covering 
either a subset or all of the exonic regions of TP53.  Several of these methods have 
been used in the published literature with varying results, making it difficult to arrive 
at definitive conclusions from the available data(63).  Because missense mutation in 
TP53 often results in p53 overexpression, high p53 expression on IHC has been 
used as a marker for TP53 mutation, and the majority of studies evaluating p53 in 
HNSCC have used IHC to assess p53 status(63).  The poor concordance between 
TP53 mutation and IHC evaluation has been demonstrated(47).  Furthermore, 
several studies have limited TP53 gene sequencing to a subset of TP53 exons 
focusing on the DNA-binding domain(44, 45), whereas more recent studies have 
evaluated the entire coding region of TP53(57, 61), perhaps leading to varying 
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results or selection bias based on the mutations that were considered versus those 
that were not.  
 
The feasibility of sequencing DNA from HNSCC tumor samples has been 
limited outside of the research setting.  Both technical and economical 
considerations have limited the use of gene sequencing in the clinical setting.  First, 
standard processing of tissue samples involves formalin-fixation and paraffin-
embedding followed by staining for pathological review.  Many patients are initially 
identified at small, community-based hospitals and are subsequently referred to 
multidisciplinary cancer centers for treatment.  Furthermore, head and neck cancer 
is commonly diagnosed from small biopsy samples, and a large fraction of patients 
are never treated surgically.  Techniques for sequencing large genomic regions 
from formalin-fixed, paraffin-embedded tissue is limited, and PCR amplification is 
often of poor quality or impossible due to DNA cross-linking and fragmentation 
secondary to the embedding process.  Therefore, current standard clinical practices 
would require repeat acquisition of tumor for genetic analysis after initial diagnosis, 
which would add increased and unnecessary risk to patients and additional, and 
perhaps unnecessary medical costs.  Furthermore, gene sequencing, until recently, 
has been prohibitively expensive, and though costs have significantly decreased, 
they remain substantial when considered for routine clinical practice.  Finally, the 
inherent and variable presence of normal tissue in biopsy samples can lead to false-
negative results when sequencing for mutations in a background of contaminating 
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wildtype copies, which is yet another limitation to routine TP53 mutation detection 
from biopsy samples.  
 
Study Rationale, Hypothesis, and Aims 
The evidence to date suggests that the TP53 gene is a potential prognostic 
biomarker for patients with HNSCC, but the limitations highlighted above are 
hurdles that must be overcome before TP53 mutation is deemed useful in the 
clinical setting.  There is a growing need to evaluate TP53 as a potential biomarker 
in specific subsets of HNSCC patients, in particular patient groups in which current 
standards of treatment are failing in a significant fraction, or those in which a 
significant proportion of patients are at high risk of treatment-related morbidity yet 
excellent outcomes are expected.  Furthermore, techniques to evaluate TP53 in the 
clinical setting must be rapid, reliable, and best performed on specimens that are 
most readily available in the clinical setting- ie. formalin-fixed, paraffin-embedded 
(FFPE) biopsy specimens.  To further advance our knowledge of the utility of TP53 
mutation as a clinical biomarker in HNSCC, we proposed the following hypothesis 
and aims: 
 
We hypothesize that TP53 mutation is associated with poor outcome in 
patients with advanced, resectable HNSCC, and that TP53 mutation can be 
reliably identified with the TP53 AmpliChip® test (Roche Molecular Systems®, 
Pleasanton, CA) from tissue that is readily available from standard biopsy 
specimens.  
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Specific Aim #1:  To determine whether TP53 mutation could be used as a 
predictor of poor outcome in advanced, resectable HNSCC treated with surgical 
resection and post-operative radiation.  
 
Before TP53 mutation can become clinically useful, it must be determined for which 
subset of patients with HNSCC this potential biomarker would be most informative.  
Patients with advanced, resectable disease are currently faced with the most 
complex treatment options, many of which involve cytotoxic therapies (eg. radiation 
and cisplatin) for which functional p53 would perhaps be the most relevant.  We 
also felt it was important to examine a cohort of patients who were all treated 
similarly in order to determine the influence of TP53 status on outcome without the 
added consideration of variability in treatments provided.  In this study, we therefore 
examined tumor samples from patients with advanced HNSCC who were uniformly 
treated with surgery and PORT.  If TP53 mutation could be used to predict poor 
outcome among this cohort of patients, it would suggest that the presence of a 
TP53 mutation may be an indication for the addition of chemotherapy to surgical 
resection and PORT.  We therefore sequenced the entire coding region of TP53 
from the DNA from tumors among this cohort of patients using standard Sanger 
sequencing, and patient records were reviewed in order to determine if the 
outcomes of local-regional recurrence, metastasis, and death were associated with 
mutation inTP53.  Our intent was to examine TP53 mutation as a prognostic factor, 
as well as to classify TP53 mutation into the nondisruptive and disruptive 
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categories, as proposed by Poeta, et al.(57), in order to determine if these factors 
were associated with poor outcome in our patient cohort. 
 
Specific Aim#2:  To assess the ability of the AmpliChip® TP53 test to identify TP53 
mutation from formalin-fixed, paraffin-embedded specimens.   
 
Previous studies have relied on sequencing from fresh frozen tissue enriched for 
high tumor content with screening and/or microdissection.  The availability of fresh 
tissue for sequencing in the clinical setting, and the potential false-negative results 
secondary to wild-type p53 contamination from surrounding or infiltrating normal 
tissue often found in standard biopsy samples, remain two hurdles limiting the 
routine use of TP53 mutation analysis.  Recent studies have evaluated a new 
technology, the TP53 AmpliChip® (Roche Molecular Systems®, Pleasanton, CA) to 
identify TP53 mutation in breast cancer and chronic lymphocytic leukemia(65, 66).  
The AmpliChip® is a microarray-based technique that interrogates each nucleotide 
in exons 2-11 of the TP53 coding regions and splice sites.  The AmpliChip® is 
therefore designed to detect single base-pair alterations only, and cannot detect 
alterations ≥ 2 bases in size .  DNA processing involves isolation, fragmentation, 
PCR amplification, and labeling.  The resulting processed DNA is then hybridized to 
the microarray and scanned.  These procedures overcome the limitations of poor 
quality DNA in FFPE tissue, and the array is designed to detect the presence of 
single nucleotide changes in the midst of a high wild-type sequence background.   
We therefore designed a pilot study to assess the utility of the TP53 AmpliChip® to 
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detect mutations in HNSCC samples.  Formalin-fixed paraffin-embedded (FFPE) 
specimens from 19 HNSCC samples were analyzed using this new technology and 
results were compared to sequencing results obtained from the standard Sanger 
technique perfomed on DNA isolated from corresponding fresh frozen tumor tissue.  
The pilot study is designed to assess the ability of the AmpliChip® to identify TP53 
mutations from a single slide of FFPE tissue, equivalent to a typical tissue sample 
that would be available with current standard biopsy protocols for HNSCC.     
 
The overall goal is to determine whether TP53 mutation can be evaluated with 
a rapid, reliable method from paraffin-embedded biopsy samples, and also to 
determine if TP53 mutation can be used to predict poor outcome among 
patients with advanced, resectable HNSCC treated with surgery and PORT.  In 
achieving these aims we intend to further advance TP53 mutation as a 
potential biomarker in HNSCC. 
19 
 
Methods 
 
Specific Aim #1:  To demonstrate that TP53 mutation is associated with poor 
outcome in advanced, resectable HNSCC treated with surgical resection and post-
operative radiation.  
 
Patient Selection and Tissue Procurement 
Patients evaluated and treated at The University of Texas MD Anderson 
Cancer Center (UTMDACC) from 1992 – 2002 were recruited to participate in a 
head and neck cancer tissue banking program under a protocol approved by the 
institutional review board (IRB).  Clinical records were reviewed retrospectively for 
these patients and TP53 gene status was determined according to a second 
protocol approved by the IRB at UTMDACC authorizing TP53 genomic analysis on 
previously banked samples.  All patients were previously untreated and received 
primary treatment of squamous cell carcinoma of the oral cavity, pharynx, or larynx, 
undergoing surgical resection followed by PORT.  Specimens were harvested from 
the tumor primary site and snap frozen at the time of surgery.   
Patients who received neoadjuvant or adjuvant chemotherapy were 
excluded.  Frozen sections from all specimens were reviewed by a member of the 
UTMDACC Pathology Department and were confirmed to be HNSCC with at least 
70% of the specimen determined to be tumor.  Clinical and pathologic factors were 
recorded, including T stage, N stage, surgical margin status, extracapsular lymph 
node extension (ECE), lymphovascular invasion (LVI), and perineural invasion 
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(PNI).  For the purposes of this study, pathology reports that did not explicitly 
identify LVI or PNI were considered to be negative for these features.  Additional 
review of the pathology slides was performed if the original pathology reports did 
not explicitly state the presence or absence of ECE or positive surgical margins. 
Generally, all patients were evaluated every 2 - 3 months for the first year 
following treatment, every 3 - 4 months the second year, and then every six months, 
thereafter.  The outcomes and dates of local recurrence (LR), local-regional 
recurrence (LRR), development of distant metastasis (DM), disease-status at last 
contact, and death were recorded. 
 
DNA Extraction and Isolation 
Approximately 10mg of tumor sample was minced and resuspended in pure 
PBS.  The sample then underwent overnight digestion with proteinase K at 55°C.  
DNA was isolated using the QIAmp® DNA mini Kit (Qiagen®, Maryland, USA), 
following the manufacturer’s protocol.  Eluted DNA was quantified using the Quant-
ItTM PicoGreen® system (Invitrogen®, Carlsbad, CA, USA). 
 
TP53 Sequencing and Classification 
The coding regions and surrounding splice sites from exons 2-11 of the TP53 
gene were evaluated via direct sequencing from genomic DNA, which was sent to 
Beckman Coulter Genomics (Beckman Coulter®, Brea, CA, USA).  Standard 
Sanger sequencing using BigDye® Terminator chemistry (Applied Biosystems® Life 
Technologies®, Carlsbad, CA, USA) was performed through the service provided 
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by the company.  TP53 point mutations were categorized as “disruptive” and “non-
disruptive”.  Disruptive mutations were defined as stop codons, or missense 
mutations occurring within the L2 or L3 loop of the key DNA-binding domain, 
leading to substitution with an amino acid of a different polarity or charge group, as 
described by Poeta, et al(57).  All other point mutations, except for splice site and 
insertion or deletion mutations (indels), were defined as non-disruptive mutations.  
Splice site mutations and indels were classified together as a separate group, and 
the disruptive and non-disruptive mutations were also categorized collectively as 
“point mutations” for portions of the analysis.  In cases where more than one 
mutation was identified and each mutation was classified into two different groups, 
TP53 status was classified according to the mutation suspected to have the more 
deleterious effect (eg. if a disruptive and a non-disruptive mutation were both 
identified, then the tumor would be classified in the TP53 disruptive mutation 
category). 
 
Statistical Analysis 
The proportion of TP53 mutations and disruptive TP53 mutations between 
different groups of patients were compared using χ2 statistics, with or without Yates’ 
correction, or Fisher exact tests where appropriate.  Each patient’s follow-up period 
was defined as the date of surgery to the date of last contact or date of death.   
Median follow –up time was calculated via the method of Schemper and Smith(67).  
Overall survival was defined as the period from the date of completion of definitive 
treatment to the date of death.  Disease-free survival (DFS) was defined as the 
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period from the date of completion of definitive treatment to the date of first 
recurrence or date of death.  Time to distant metastasis (DM) was defined as the 
date of the completion of definitive treatment to the date of development of distant 
metastasis.  Patients who died prior to developing distant metastasis were censored 
for analysis of this outcome.  Curves for overall survival (OS), DFS, and the 
development of DM between TP53 mutant and wild-type groups, as well as 
between disruptive, non-disruptive, and splice site/indels were estimated using the 
Kaplan-Meier method, and Log Rank statistics were used to calculate the 
significance of differences observed.  Univariate and multivariate proportional 
hazards models were generated to identify prognostic factors that were significantly 
associated with reduced OS, DFS, and DM.  For all values, a threshold of p < 0.05 
was accepted as statistically significant.     
 
Specific Aim#2:  To assess the ability of the TP53 AmpliChip® to identify TP53 
mutation from formalin-fixed, paraffin-embedded specimens.   
 
Tumor Specimens and Sample Preparation 
Additional HNSCC tumor specimens were evaluated using both Sanger 
sequencing of TP53 and using the AmpliChip® TP53 assay (Roche Molecular 
Systems®, Pleasanton, CA).  These samples were obtained from patients who had 
consented to provide tumor specimens at the time of surgical resection, to be stored 
as part of a Head and Neck Cancer tumor bank at UTMDACC, opened and 
maintained under an active IRB approved protocol.  An additional IRB-approved 
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protocol was obtained authorizing TP53 genomic analysis.  Fresh tissue was snap 
frozen in liquid nitrogen at the time of acquisition and stored at -80 °C.  Tissue 
samples were deemed to be HNSCC after review by a pathologist at the time of 
biopsy.           
Each specimen was divided in half, with one half designated for Sanger 
sequencing and the other half designated for TP53 AmpliChip® testing.  For Sanger 
sequencing, samples were embedded in Optimal Cutting Compound (OCT) 
(Sakura®, Torrance, CA), frozen in dry ice conditions, and stored at -80 °C until 
DNA isolation.  For TP53 AmpliChip® analysis, specimens were fixed in formalin 
and embedded in paraffin.  A representative slide was cut from this block and 
stained with hematoxylin and eosin (H&E) stains.  Each slide was reviewed by two 
independent members of the laboratory (one postdoctoral fellow, and one research 
instructor with formal pathology training) who graded each slide for percent tumor in 
the entire specimen, and percent tumor composing the most dense region of each 
sample- these two percentages were recorded and averaged to arrive at the final 
call.  The time from tissue acquisition to paraffin-embedding, acquisition to TP53 
analysis, and from paraffin-embedding to TP53 analysis was recorded.  
 
Patient Data 
A retrospective chart review was performed under an IRB-approved protocol, 
and the following data were recorded:  date of diagnosis, date of surgical resection, 
disease stage, primary or recurrent disease, treatments rendered, date of last 
treatment of initial disease, date of last contact, presence or absence of LRR, the 
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date LRR presented, presence or absence of the development of DM, date that DM 
presented, date of last contact, and vital status.         
 
DNA Isolation and TP53 Sequencing 
For Sanger sequencing analysis, a cryotome was used to cut fifteen 10 uM 
sections from the specimens previously embedded in OCT.  From these sections, 
the RecoverAllTM Total Nucleic Acid Isolation Kit (Ambion®, Applied Biosystems®, 
Austin, Tx)  was used per the manufacturer protocol to extract genomic DNA.  The 
amount of DNA isolated and the concentration was then analyzed using the 
NanoDropTM 2000 (Thermo Fisher Scientific®, Wilmington, DE).  DNA samples 
were then sent to the Baylor College of Medicine Human Genome Sequencing 
Center for sequencing of the coding regions and splice regions of TP53 for exons 2-
11. 
 
Sample Preparation for the AmpliChip® p53 Assay and Analysis 
The DNA isolation, preparation, and analysis for the AmpliChip® p53 assay 
are under development by Roche Molecular Systems® and not yet commercially 
available.  Paraffin-embedded slides were processed by Roche® under a research 
agreement with our group.  After formalin-fixation and paraffin embedding, one slide 
was cut from each block for H&E staining, and a second 10um-thick section was cut 
and mounted on a second slide.  In cases of small samples, two or three sections 
were mounted per slide.  H&E slides were evaluated by two independent members 
of the laboratory (one of whom is a pathologist by training) who provided an 
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estimate of percent tumor of the entire sample and for the most dense regions of 
tumor for each section.  The estimates from the two evaluators were averaged to 
arrive at the reported result.  Sections of most dense tumor were circled for 
macrodissection.  These slides were then sent to the Roche® laboratory, where 
they were macrodissected and prepared for AmpliChip® testing as previously 
reported (66, 68).   
Briefly, slides were deparaffinized, DNA was extracted and isolated, 
fragmented, PCR-amplified, biotin-labeled, and hybridized to the AmpliChip® p53 
arrays.  The arrays were then scanned using an Affymetrix® Dx2 Scanner and data 
was analyzed to arrive at the TP53 sequence of each sample.   
 
Statistical Analysis 
Kaplan-Meier survival analysis for the patients was stratified by TP53 status, 
and generated for each of the two TP53 analysis methods for comparative 
purposes.  This analysis was used to arrive at median disease-free survival for each 
group.   
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Results 
Specific Aim #1:  To demonstrate that TP53 mutation is associated with poor 
outcome in advanced, resectable HNSCC treated with surgical resection and post-
operative radiation.  
 
Patient characteristics and follow-up  
We initially identified 88 patients that had received surgical resection and 
PORT as treatment for HNSCC who had DNA available for this study.  Five  
patients were excluded because their tumors arose in sites that the authors felt 
were not appropriate for evaluation in this cohort (2 maxillary sinus, 1 lip, and 2 from 
perioral skin), and five additional patients were excluded because they had received 
neoadjuvant or adjuvant chemotherapy in addition to PORT as part of their 
treatment regimen.  A significant portion of the TP53 gene in 4 additional samples 
could not be amplified and sequenced.  Therefore, a total of 74 patients were 
evaluated in this study (Table-1).   
 The median age of the patients evaluated was 57 years (range 34 – 82).  
There were 50 male and 24 female patients who had primary tumors from the oral 
cavity (n=32), hypopharynx (n = 18), larynx (n = 16) or oropharynx (n=8).  Sixty-five 
patients were determined to have stage IV disease, 3 patients stage III, and only 6 
patients stage I or II.  Sixty-two patients (84%) presented with T3 or T4 tumors at 
the primary site, and 46 (62%) had N2b or greater nodal burden at diagnosis.  
Twenty-seven (36%) patients were noted on pathology to have PNI, and 17 (23%) 
had signs of LVI.  Forty-eight patients (65%) had ECE, and 13 (18%) had positive  
27 
 
 
Table-1.  Patients included and excluded, and TP53 mutations identified. 
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margins after surgical resection.  Table-2 summarizes the clinical and demographic 
characteristics of the patients. 
 
 
 
 
Table-2.  Patient characteristics and distribution of TP53 mutations. 
*Proportions of patients with TP53 mutation or disruptive mutation among patients with hypopharyngeal  
primary tumors were compared to those arising from the other sites 
**Patients with stage T1 or T2 disease were compared to those with stage T3 and T4 disease. 
†Patients with stage N0 – N2a disease were compared to those with N2b or greater disease. 
‡Patients with  ECS or Positive surgical margins were compared to those who did not have these factors. 
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The follow-up period for this group of patients ranged from 6.65 years to 
22.20 years, with a median follow-up of 13.05 years.  At the last review, 60 patients 
had died (range of time to death, 32 days to 13.7 years; median overall survival was 
2.73 years), 35 had no evidence of disease (NED) at last contact or death, 26 had 
LRR or persistent disease, and 20 developed DM.   
 
TP53 mutation and clinical-pathologic features 
Forty-seven mutations in TP53 were identified in 43 patients (57%).  There 
were 18 disruptive, 18 non-disruptive mutations, 7 indel, and 4 splice site mutations.  
The majority of missense mutations were within the DNA-binding domain (Figure-3), 
with several located in known TP53 hotspot sites (eg. codons 175, 245, 273).  A list 
of the mutations identified is provided in Table-1.   
TP53 mutations were found in tumors from 26 (63%) of the patients with T4 
disease, 30 (65%) of the patients with N2b or greater disease, and 31 (65%) of 
patients with ECE.  The proportions of TP53 mutations and disruptive mutations 
among the patients studied are presented in Table-2.  Only hypopharyngeal primary 
site was associated with a significantly increased proportion of TP53 mutations 
(p=0.015), but the proportion of disruptive TP53 mutations did not appear enriched 
in this group.  There did appear to be a higher proportion of disruptive mutations 
among the group of patients with either ECE or positive surgical margins, but this 
difference did not reach statistical significance (p= 0.06).  Among the 43 patients 
with tumors harboring mutant TP53, 13 (30%) developed LRR, and 16 (37%) 
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developed DM, compared to 12 (39%) and 6 (19%), respectively in the 31 patients 
with p53 wildtype tumors.  Twelve of 16 patients (75%) with tumors with disruptive 
mutations developed relapse:  eight patients (50%) developed LRR, and eight 
(50%) developed DM (4 of these patients developed both LRR and DM).  
Figure-3.  (A.) Frequency of point mutations in TP53.  (B.) Proportions of patients 
with mutation in TP53 and proportion of mutation types identified. * Indicates 
position of disruptive mutations identified. 
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Survival analysis and risk models    
Univariate analysis showed that several clinico-pathologic factors were 
associated with the endpoints of OS, DFS, and DM (Table-3).  Stage T3 or T4 
disease, N2b or greater nodal burden, and ECE and positive surgical margins were 
significantly associated with reduced OS and DFS.  N2b or greater nodal disease 
was associated with DM. 
 
 
 
  
 
 
Table-3.  Univariate Analysis  – factors associated with overall survival, disease-free survival, 
and the development of distant metastasis. 
 
*indicates significance of Log Rank p <0.05;  Abbreviations:  Neg Marg (negative surgical margins), Pos Marg 
(positive surgical margins), ECE (extracapsular spread of regional disease), LVI (lymphovascular invasion), PNI 
(perineural invasion), WT (wildtype TP53), WT-Other Mutations (wildtype T53, splice-site, insertion-deletion, and 
non-disruptive mutations), WT-Splc-Indel (wildtype TP53, splice site, or insertion-deletion mutation) 
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Figure-4.  Overall (A.) and disease-free 
survival (B.) for patients with HNSCC tumors 
carrying wildtype TP53 versus mutant TP53. 
 
Kaplan-Meier survival estimates 
showed that TP53 mutation was 
associated with decreased DFS at 
5 years (31.0% vs. 43.4%, p53 
mutant group vs. the wild-type 
p53 group, respectively, Log rank 
p = 0.049) as shown in Figure-4.  
When TP53 mutations were 
classified into point mutations vs. 
splice-site or indel mutations and 
wildtype p53, point mutations 
were associated with worse 
outcomes for all three endpoints 
(Figure-5; Table-3).  Kaplan-
Meier plots displaying outcomes 
after further division of TP53 
point mutations into non-disruptive and disruptive mutations showed that the  
patients with tumors bearing disruptive TP53 mutations had the worst outcome for 
all three endpoints (Figure-6 and Figure-7).  As an independent factor, disruptive 
mutation was strongly associated with decreased DFS (HR 2.24, 95% CI 1.22 – 
u4.12; Log Rank p = 0.03) and DM (HR 3.62, 95% CI 1.49 – 8.85, Log Rank p = 
0.009).   
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In multivariate analysis using Cox 
proportional hazards models (Table-4), 
Stage T3 or T4 disease remained a 
significant factor associated with OS 
and DFS, and N2b or greater disease 
was associated with decreased OS 
and DM.  Point mutation in TP53 
remained a significant factor 
associated with poor outcome for all 
three endpoints after adjustment for 
other significant factors.  When models 
using disruptive mutation were 
examined, disruptive mutation was 
strongly associated with DM (HR 4.0, 
95%CI 1.61 – 9.90, p = 0.003).  
Interestingly, the presence of positive 
surgical margins and/or ECE were not 
significant factors for any of the 
multivariate models examining this 
patient cohort. 
 
 
 
Figure-5.  Kaplan-Meier curves for  
Overall survival (A.), disease-free survival (B.), 
and distant metastasis (C.) for patients with 
tumors carrying wildtype TP53, splice-site or 
insertion/deletion (splice-indel) TP53 mutations, 
or TP53 point mutations (defined as either 
nondisruptive or disruptive).  
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Figure-6.  Overall (A.) and disease-free survival (B.) for patients with HNSCC tumors 
carrying wildtype TP53, splice-site or insertion/deletion (splice-indel) TP53 mutations, 
nondisruptive TP53 mutations, or disruptive TP53 mutations. 
 
 
 
 
 
 
Figure-7. Distant metastasis in patients with tumors carrying wildtype TP53 vs. mutant 
TP53 (A.) and in patients with tumors carrying wildtype TP53, splice-site or 
insertion/deletion (splice-indel) TP53 mutations, nondisruptive TP53 mutations, or 
disruptive TP53 mutation (B.). 
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Table-4.  Multivariate analysis- factors associated with overall survival, disease-free 
survival, and distant metastasis.  Two models were reviewed- one using p53 disruptive 
mutation as a prognostic factor, and a second model using TP53 point mutation (combined 
disruptive and –nondisruptive mutation vs. other patients) as a prognostic factor.    
 
Table-5.  Patient Characteristics  
 
 
 
Specific Aim#2:  To assess the ability of the  
AmpliChip® p53 test to identify TP53 mutation from 
formalin-fixed, paraffin-embedded specimens.   
 
Patient Characteristics 
Nineteen patients were evaluated with both TP53 
AmpliChip® and Sanger Sequencing.  The median 
follow-up for this group of patients was 28.16 months.  
The majority of tumors (17 of 19) were from the oral 
cavity.  Thirteen patients had a significant smoking 
history and one patient had a history of chewing betel 
quid.  The characteristics of this sample set are 
summarized in Table-5.  Among these patients, 10 
developed disease recurrence and 5 patients died during 
the follow-up period.  
*indicates significance <0.05;  Abbreviations:  Pos Marg (positive surgical margins), ECE (extracapsular 
spread of regional disease), NS = not a significant factor in the model, N/A = not applicable (no patients 
with T1/T2 disease developed distant metastasis)  
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TP53 sequencing results 
Sanger sequencing identified 12 mutations in 12 patients (41% of cohort).  There 
were 5 missense mutations, 4 nonsense mutations, 1 splice mutations, and 2 
deletions using this sequencing technique.  TP53 AmpliChip® results were obtained 
from a single paraffin-embedded slide in all 19 cases.  The average area of tumor 
from which DNA was isolated was 28.14 mm2 (range 15 mm2 - 84 mm2), calculated 
from the tumor area multiplied by the number of sections per slide.  This method 
identified 17 mutations in 15 patients (79% of cohort).  There were twelve missense 
mutations, 3 nonsense mutations, 1 splice mutation, and 1 deletion (frameshift) 
mutation using the AmpliChip®.  The two sequencing techniques agreed in 11 of 19 
patients (58%).  The AmpliChip® identified 5 missense, 3 nonsense, 1 splice site, 
and 1 frameshift mutation (1bp deletion) that were also detected with Sanger 
sequencing, and the AmpliChip® identified an additional 7 missense mutations.  
The Sanger method identified 1 nonsense mutation and 1 two bp deletion that were 
not detected with the AmpliChip®.   The two methods agreed upon 1 wildtype call.   
These results are presented in Table-6. 
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Survival Analysis 
Disease-free survival was calculated for the patient cohort comparing the 
outcome in patients with wildtype TP53 to those with mutant TP53 as determined by 
the two sequencing methods.  When results from the Sanger sequencing method 
were used to stratify patients, the median disease-free survival for the wildtype 
TP53 group was 15.42 months, versus 33.03 months in the TP53 mutant group.  
When the TP53 AmpliChip® was used, the median disease-free survival was 35.08 
months in the TP53 wildtype group versus 33.02 months for the TP53 mutant group.  
In both cases, a significant difference was not observed between the wildtype and 
mutant groups when survival curves were compared using the Log Rank test (data 
not shown).  
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Discussion 
Several reports have linked TP53 mutation to poor outcome in HNSCC.  The 
work by Poeta, et al. provides strong evidence that TP53 mutation, particularly 
disruptive TP53 mutation, is associated with decreased overall and progression-free 
survival(57).  In their study, 131 patients received surgery alone and 203 patients 
received additional treatment.  Seventy-eight patients received salvage surgical 
resection, suggesting surgery was not the primary modality of treatment in at least 
the majority of this subset.  The variability in treatments provided to the patients in 
this study makes it difficult to determine for which patients TP53 mutation is most 
relevant.  In addition, the pattern of relapse was not reported.  An earlier study by 
Erber, et al., classified TP53 mutation into contact mutations (those that disrupted 
the core DNA-binding region) and structural mutations (those that alter the 
conformation of p53), a system defined according to the crystal structure of the p53 
molecule(62).  TP53 contact mutations were associated with poor outcome among 
86 patients with HNSCC(45).  Sixty-six of 86 (77%) of the patients in this study 
received PORT.  A similar paper by Koch, et al., examined 110 patients who 
received either primary or adjuvant radiation therapy, and concluded that local-
regional failure was associated with mutation in TP53(44).  Most recently, 
Lindenbergh, et al. evaluated TP53 mutation and HPV-status among 141 patients 
with oral cavity or oropharyngeal squamous carcinoma who received either surgery 
or surgery and radiation(61), and determined that truncating mutations (defined as 
nonsense mutations, splice mutations, or frameshift mutations) were associated 
with the poorest outcome.  This group found that the truncation categorization was 
40 
 
more discriminating than several other classification systems, including the 
disruptive/nondisruptive system supported by Poeta, et al(57) and by our study.   
The evidence to date has suggested that TP53 mutation may be a predictor for poor 
outcome among patients treated with PORT, however, there is debate as to which 
TP53 mutation classification system is most prognostic.    
Our report is, to our knowledge, the first to focus on a group of HNSCC 
patients with locally-advanced disease treated uniformly with surgery and PORT.  
We have demonstrated that p53 point mutation is associated with decreased OS 
and DFS.  In addition, thorough review of patterns of failure in our patient set 
enabled us to detect that disruptive mutation was strongly associated with the 
occurrence of distant metastasis.   
Our study suggests that patients with HNSCC that carry TP53 point mutation, 
especially disruptive mutations, may require additional treatment to PORT in order 
to improve outcome.  Multiple studies have shown the benefit of CCR for enhancing 
local-regional control and OS in advanced HNSCC in both the adjuvant and 
definitive treatment settings(6, 13, 14, 69).  Similarly, induction chemotherapy may 
significantly reduce the rate of distant metastasis(69, 70).  Presently, the efficacy 
and potential toxicity of induction chemotherapy followed by concomitant 
chemoradiotherapy is under study for patients with regionally advanced 
disease(71).  More information is needed regarding the significance of TP53 as a 
biomarker in patients undergoing sequential induction chemotherapy and radiation 
or concomitant chemoradiotherapy.  TP53 as a biomarker of virulent disease may 
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become an important selection factor for patients being considered for treatment 
with these combined therapeutic options. 
Several studies have shown that HNSCC tumors that retain wild-type p53 are 
more sensitive to cisplatin-based chemotherapy regimens, whereas loss of p53 
function is associated with resistance to cisplatin(72-74).  Studies in ovarian cancer 
have shown that addition of taxane therapy to cisplatin can improve responses 
among patients with tumors carrying a mutation in TP53(75, 76).  A recent phase II 
trial, RTOG 0024, reported promising results incorporating early post-operative 
paclitaxel followed by concurrent paclitaxel-cisplatin with radiation in patients with 
advanced, resectable HNSCC as compared to historical controls treated with 
concurrent cisplatin alone and post-operative radiation(77).  Future prospective 
trials incorporating evaluation of TP53 mutation are necessary to determine if 
alternative drug regimens such as these can improve local-regional and distant 
control in the setting of tumors with mutations in TP53 treated with surgery and 
PORT.   
Our study design did not aim at exploring the mechanism by which TP53 
mutation affects tumor biology, thus we can only speculate as to why TP53 point 
mutation and disruptive mutations were associated with poor outcome.  It is 
possible that PORT had a reduced effect in patients whose tumors had TP53 point 
mutations/disruptive mutations as compared to those with wild-type p53 or splice-
site/indel mutations in our series.  P53 is known to be a key regulator of the 
response to DNA damage, influencing several pathways leading to cell cycle arrest, 
DNA repair, autophagy, senescence, and apoptosis(36).  Disruption of p53 leads to 
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altered regulation of each of these responses, which likely contributes to resistance 
to radiation therapy in tumor cells(78).  Additionally, expression of mutant p53 can 
have gain-of-function activity, which has been reported to increase genetic 
instability and alter the response to DNA damage(79, 80).  Preclinical evaluation of 
TP53 mutations and the response of HNSCC cells to radiation have led to mixed 
conclusions(81), and remains to be further elucidated.  
Another interesting observation is the association of TP53 point and 
disruptive mutations with the development of DM in our study.  Among the largest 
studies to evaluate TP53 in HNSCC, several have found an association between 
specific TP53 mutations and OS and DFS in HNSCC(45, 57, 61), but only one study 
examined DM, specifically(44).  Koch, et al. did record DM in their report, but the 
proportions of patients who developed DM in the TP53 wildtype and the TP53 
mutant groups were roughly equivalent, and no further evaluation regarding DM 
was reported.  Two notable preclinical studies have described metastasis as a 
potential gain-of-function property of the of R172H-TP53 mutation in in vivo ‘knock-
in’ mouse models of cutaneous(82) and pancreatic cancers(83).  In our patient set, 
we have identified an association of TP53 point mutations and disruptive mutations 
with the development of DM.  Whether gain-of-function TP53 mutations are 
contributing to metastasis in HNSCC remains to be elucidated.          
A potential flaw of our study is that 8 patients (11%) had oropharyngeal 
cancer, and the HPV status of these tumors is not known.  Notably, only 5 of these 
patients retained wildtype TP53.  Five of the oropharyngeal cancer patients had no 
evidence of disease at last follow up, and two of these patients who did not recur 
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had tumors with mutations in TP53.  Thus, there may have been HPV positive 
tumors among our patient set, however the impact these patients may have had on 
the survival outcomes evaluated in our study is likely negligible.  This is in contrast 
to previous reports linking TP53 mutation to poor outcome, in which substantial 
numbers of patients with oropharyngeal cancer were evaluated(45, 57, 61).  The 
study by Lindenbergh, et al.(61) did evaluate HPV DNA and E6/E7 expression, 
identifying HPV-related disease in 12 cases.  The cohort in this study were all 
treated with surgery or surgery and radiotherapy.  As primary surgery is not the 
standard recommendation for oropharyngeal cancer in the large majority of centers 
in the United States, it is difficult to interpret the results regarding the 43 patients 
with oropharyngeal cancer that were evaluated in this study.  TP53 mutations in 
patients with HPV-negative oropharyngeal squamous cell carcinoma have been 
evaluated by Fallai, et al., and disruptive TP53 mutation did not appear to be 
associated with poor outcome in this study (64), however further evaluation of this 
patient population is necessary. 
 The evidence to date has supported TP53 as a potentially useful marker in 
the management of HNSCC.  If TP53 sequencing is to become part of the routine 
diagnostic regimen, the question arises as to what methodology would best identify 
TP53 mutations in tumor specimens when a patient is initially diagnosed with 
HNSCC.  Our pilot study of the TP53 AmpliChip® has demonstrated the utility of 
this method.  As the AmpliChip® identified mutations in 5 additional patients who 
were called as wildtype with standard sequencing methods, it would appear that the 
AmpliChip® is a more sensitive technique for identifying mutations, however 
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additional testing of these samples with a third chemistry is necessary to determine 
whether the results from the Sanger method or AmpliChip® are true in the 
discordant cases.  One could argue that the Sanger method would have been more 
accurate if microdissection were performed on these samples, but the tumor volume 
necessary to obtain adequate DNA for this technique would required time-
consuming microdissection of several slides given the small area of tumor present 
in these samples.  Typical biopsy samples are small, and often contaminated with a 
significant amount of normal stroma or lymphoid tissue.  Furthermore, initial biopsy 
material is often formalin-fixed and paraffin embedded prior to ultimate referral to 
the head and neck oncology team.  Thus, the TP53 AmpliChip® appears to be a 
superior method given the ease of processing from readily available materials, as 
well as concerning the seemingly high accuracy of this method despite fixation and 
embedding of the tissue and the ability to call mutations in a significant background 
of wildtype contamination.   
The AmpliChip® offers other potential applications, including TP53 
sequencing from lymph node micrometastases, which often have a high degree of 
contaminating normal surrounding lymphocytes and stroma, and sequencing from 
fine needle aspiration samples.  Testing of this method in these settings has not 
been undertaken and is a potential area of further study.      
One could argue that the additional mutations identified in this pilot study 
represent false-positive mutation calls.  This would seem unlikely given the identical 
calls made in the 11 concordant samples, but a third chemistry  sequencing 
analysis (4-5-4 sequencing) from the DNA isolated after microdissection is currently 
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underway in order to determine if additional mutations called by AmpliChip® or the 
Sanger method were true positive calls.  The fact that there was considerable 
discrepancy between the two methodologies used to determine TP53 status in our 
pilot study suggests that all studies that have examined TP53 in HNSCC should be 
reviewed with some caution and skepticism.  Differing techniques in tissue 
processing, variability and inaccuracy in pathologic review to determine percentage 
of tumor, extent of microdissection, and methodologies used to detect TP53 
mutations can each alter the proportion of false-negative TP53 mutation results, and 
has surely contributed to the variation in conclusions drawn from the existing 
literature studying TP53 in HNSCC.  Our pilot study comparing the AmpliChip® and 
standard sequencing highlights this fact, and further comparative studies between 
TP53 mutation detection methods should be undertaken in order to arrive at a 
consensus as to the best method to obtain the most reliable TP53 sequence results 
in a cost-efficient manner.         
  
Future Directions  
 In selecting patients with advanced, resectable disease who were treated 
uniformly with surgery and PORT, we have isolated a patient subset that is in need 
of new management options that improve outcome.  We have shown that TP53 
mutation can potentially be used as a marker to predict for a worse outcome and 
the development of DM, and the presence of TP53 mutation in advanced, 
resectable tumors may warrant escalated therapy.  Validation of our findings and 
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those of others requires prospective evaluation of specific therapeutic interventions 
of site- and stage-matched patients with and without TP53 mutations.  Current 
studies of HNSCC at UTMDACC designed to examine TP53 mutation have opened, 
and the author is aware of a recent European study that intends to stratify patients 
by TP53 mutation and examine the response to induction therapy with a taxane-
based regimen. 
 Our work with the TP53 AmpliChip® suggests that this is a promising method 
that could be introduced into the clinical setting and be a powerful research tool that 
allows rapid and reliable evaluation of TP53 from large sets of archived FFPE 
samples.  To further test this method, the author and supervisory professor have 
initiated a large retrospective study utilizing the AmpliChip® to evaluate TP53 from 
archived oral cavity squamous cell cancer specimens from patients treated at 
institutions from several regions of the world.  The goal is to study both the 
prevalence of TP53 mutations, and the association of TP53 mutation with outcome 
in the setting of different risk-factors for this disease (eg. tobacco smoke vs. alcohol 
use vs. betel quid use).  TP53 AmpliChip® results will be validated in a subset of 
these patients with 4-5-4 sequencing in order to establish the error rate of this 
method in this patient population.     
 
Conclusions 
Patients with advanced, resectable HNSCC and point mutations in TP53, 
particularly disruptive mutations, have a poor prognosis if treated with standard 
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therapeutic approaches.  Our findings need to be validated in prospective trials.  If 
so, novel treatment strategies targeting the primary mechanisms of treatment failure 
must be developed.  Consideration should be given to trials investigating the 
efficacy of systemic-dose level chemotherapy, either as an induction or possibly an 
adjuvant strategy, in an attempt to decrease the rate of distant disease recurrence 
in this subgroup.  As support for TP53 mutation analysis as a biomarker in the 
management of HNSCC grows, there is a necessity for a reliable, rapid method of 
TP53 mutation detection from available tissue.  Our pilot study examining the 
AmpliChip® p53 test demonstrates the potential advantages and applications of this 
method, particularly for HNSCC. 
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